Pharmaceutical News

RSS

Researchers identify biochemical mechanism that could lead to 'chemo brain'

UNC School of Medicine researchers have found for the first time a biochemical mechanism that could be a cause of "chemo brain" - the neurological side effects such as memory loss, confusion, difficulty thinking, and trouble concentrating that many cancer patients experience while on chemotherapy to treat tumors in other parts of the body.

4 Dec 2014

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital.

4 Dec 2014

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, today announces that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties.

4 Dec 2014

PulmoFlow's nebulized drug and device combination gets FDA approval for cystic fibrosis

On Tuesday, the FDA granted final approval of PulmoFlow, Inc.'s New Drug Application for Kitabis Pak – a co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS Nebulizer. This is the first nebulized drug and device combination to be approved for patients with cystic fibrosis.

3 Dec 2014

Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Although some guidelines recommend use of bisphosphonates (a class of drugs used to strengthen bone) for men on androgen deprivation therapy, an analysis finds that prescriptions for these drugs remains low, even for those men at high risk of subsequent fractures, according to a study in the December 3 issue of JAMA.

3 Dec 2014

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Monash University and 60P Australia Pty Ltd, a subsidiary of 60° Pharmaceuticals LLC, have announced today an exclusive partnering deal, with 60P obtaining rights to develop the drug Fenretinide for dengue fever.

2 Dec 2014

Perrigo receives final FDA approval for diclofenac sodium topical solution 1.5% w/w

Perrigo Company plc today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for diclofenac sodium topical solution 1.5% w/w. Shipments to our pharmacy customers have commenced.

2 Dec 2014

BioPharmX submits request for pre-IND meeting to FDA for topical antibiotic acne compound

BioPharmX Corporation, a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration for the company's topical antibiotic acne compound currently under development.

2 Dec 2014

Study examines rate of psychotropic medication prescribed to children in Kentucky

Researchers with the Child and Adolescent Health Research Design and Support Unit (CAHRDS Unit) at the University of Louisville have begun a study to examine one of Kentucky's most vexing children's health issues: the higher-than-average rate of psychotropic medication being prescribed to children in the Bluegrass State.

2 Dec 2014

Antacid medicines improve overall survival in patients with head and neck cancer

Patients with head and neck cancer who used antacid medicines to control acid reflux had better overall survival, according to a new study from the University of Michigan Comprehensive Cancer Center.

2 Dec 2014

Otsuka Pharmaceutical to acquire Avanir Pharmaceuticals for $3.5B

Avanir Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement with Otsuka Pharmaceutical Co., Ltd. pursuant to which Otsuka will acquire Avanir for $17.00 per share in cash.

2 Dec 2014

Co-enzyme Q supplement lowers age-associated damage that leads to heart disease

New research involving rats, and published in the December 2014 issue of The FASEB Journal, suggests that if you were born at a low birth weight, supplemental co-enzyme Q (CoQ) may lower your risk for heart disease.

2 Dec 2014

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast and colon cancers, according to two studies led by researchers at the Icahn School of Medicine at Mount Sinai and published today in the Proceedings of the National Academy of Sciences.

2 Dec 2014

Ligand indazole chloride improves motor function, study shows

Multiple sclerosis (MS), an autoimmune disease of the brain and spinal cord, affects about 2.3 million people worldwide (400,000 in the United States). Affecting more women than men, it can be seen at any age, although it is most commonly diagnosed between the ages of 20 and 40.

2 Dec 2014

Antibiotic resistance: Theme for next Uppsala Health Summit

The theme for the next Uppsala Health Summit, to be held in Uppsala on 2-3 June 2015, is antibiotic resistance -- one of the biggest global health challenges of our day.

2 Dec 2014

Pain medicine specialist receives award for new advances in oral fluid testing

This year's Eastern Pain Society Scientific meeting was held at Mount Sinai Beth Israel Medical Center in New York City in late October and is one of the largest meetings of pain physicians and fellows in the tri-state area.

2 Dec 2014

Researchers warn that Vitamin A deficiency can cause eye problems

Obese patients who have undergone bariatric surgery to shed weight should take the supplements prescribed to them to protect their eyes. Taking in too little Vitamin A, in particular, could in some cases actually cause night blindness, dry eyes, corneal ulcers, and in extreme cases total blindness. This advice comes from Rui Azevedo Guerreiro and Rui Ribeiro of the Centro Hospitalar de Lisboa Central in Portugal, who reviewed what little research there currently is on the occurrence of eye conditions following bariatric surgery.

2 Dec 2014

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Nektar Therapeutics reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

From Baxter International Inc. 1 Dec 2014

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO).

1 Dec 2014

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs.

1 Dec 2014

Pharmaceutical News

Researchers identify biochemical mechanism that could lead to 'chemo brain'

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

PulmoFlow's nebulized drug and device combination gets FDA approval for cystic fibrosis

Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Perrigo receives final FDA approval for diclofenac sodium topical solution 1.5% w/w

BioPharmX submits request for pre-IND meeting to FDA for topical antibiotic acne compound

Study examines rate of psychotropic medication prescribed to children in Kentucky

Antacid medicines improve overall survival in patients with head and neck cancer

Otsuka Pharmaceutical to acquire Avanir Pharmaceuticals for $3.5B

Co-enzyme Q supplement lowers age-associated damage that leads to heart disease

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

Ligand indazole chloride improves motor function, study shows

Antibiotic resistance: Theme for next Uppsala Health Summit

Pain medicine specialist receives award for new advances in oral fluid testing

Researchers warn that Vitamin A deficiency can cause eye problems

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Eylea receives Health Canada approval for treatment of CRVO and DME

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News